Apyx Medical Corp (APYX)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$3.05-0.33%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · APYX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to grow total revenue with a focus on Surgical Aesthetics segment and reaffirm FY2026 revenue guidance of $59.0M to $60.0M.
Stated as a priority in 4 of last 4 quarters. Total revenue grew 22% year-over-year to $13.9 million in Q2 2026 from $11.4 million in Q2 2025. Management reaffirmed FY2026 revenue guidance at $59.0 million to $60.0 million, up from prior year revenue of $52.8 million. The trajectory is delivering consistent growth aligned with guidance.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million”
“Raised total revenue guidance for FY2026 to a range of $59.0 million to $60.0 million”
“Expect FY2026 total revenue in the range of $57.5 million to $58.5 million”
“Increased total revenue guidance for FY2025 to a range of $50.5 million to $52.5 million”
Launch and commercialize the power liposuction handpiece for AYON platform to enhance surgical aesthetics offerings.
Stated as a priority in 2 of last 2 quarters. Management received FDA clearance for AYON's power liposuction capability in Q1 2026 and commenced limited commercial shipments in June 2026. This is a new product expansion with initial rollout underway, showing early execution on the strategic product enhancement.
“Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026”
“Received expanded 510(k) clearance from FDA for AYON to include power liposuction; limited commercial launch planned”
Publish and promote clinical data supporting combined treatment using Avéli and Renuvion for cellulite and skin laxity improvements.
Newly stated in 2026-Q2. Management published clinical study data demonstrating up to 81.8% of patients showed improvement in cellulite appearance and measurable tissue remodeling. This priority is recent with initial clinical evidence published, indicating early progress in product clinical validation.
Focus on improving operating income and reducing net losses through cost management and revenue growth.
Stated as a priority in 4 of last 4 quarters. Operating loss improved from $2.6 million in Q1 2026 to $1.8 million in Q2 2026, and adjusted EBITDA loss narrowed from $2.0 million in Q2 2025 to $0.7 million in Q2 2026. Despite ongoing net losses, the trajectory shows progress in reducing operating losses consistent with management focus.
“Operating loss of $1.8 million and adjusted EBITDA loss of $0.7 million in Q2 2026”
“Operating loss of $2.6 million and adjusted EBITDA loss improved from prior year”
“Operating income of $11,000 in Q4 2025, improved from prior quarters”
“Operating loss of $832,000 in Q3 2025, showing improvement from earlier losses”
Focus on improving operating income to reduce losses and move toward profitability.
Over the trailing year it converted 0.42x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.